array:19 [
  "pii" => "X0211699504029786"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:10"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2050
    "formatos" => array:3 [
      "EPUB" => 221
      "HTML" => 1380
      "PDF" => 449
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029778"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:11-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2581
      "formatos" => array:3 [
        "EPUB" => 227
        "HTML" => 1872
        "PDF" => 482
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Efecto del losartan sobre la muerte cardíaca súbita en personas con diabetes: estudio LIFE"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "11"
          "paginaFinal" => "12"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L. LINDHOLM"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "L. LINDHOLM"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029778?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029778/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029794"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:8-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3584
      "formatos" => array:3 [
        "EPUB" => 259
        "HTML" => 2623
        "PDF" => 702
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Óxido nítrico y remodelación vascular: papel de las metalopreatasas de matriz extracelular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "8"
          "paginaFinal" => "9"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S. LAMAS , C. ZARAGOZA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "S. LAMAS , C. ZARAGOZA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029794?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029794/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "10"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "D. DE ZEEUW"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "D. DE ZEEUW"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión D. de Zeeuw University Medical Center. Groningen. The Netherlands. Patients with renal disease not only run a great risk of end-stage-renal failure, but also high risk for cardiovascular morbidity and mortality. Indeed, a decreased glomerular filtration rate or a excessive leak of proteins in the urine are prime risk markers for CV morbidity and mortality. As far as protein leaks are concerned, even low range leakage called microalbuminuria (30-300 mg/day) appears to be such a marker. The classical cardiovascular risk profiling is based on glucose metabolism (diabetes), blood pressure, cholesterol, smoking (overweight, and lifestyle). These parameters not only allow us to classify the risk of a patient in the office, but they also allowed us to justify our therapeutic strategies. These therapies are aimed at reducing these risk factors/markers. Indeed, metabolic control of glucose was a big step in preventing the life threatening end-organ effects of type 2 diabetes. Even more impressive effects were seen when one controls blood pressure on end-organ damage. Recently, lowering of cholesterol has been added to this cardiovascular protective armamentarium. By far the biggest additive step has been made recently by the introduction of tools to intervene in the renin-angiotensin-aldosteron system, such as ACE-inhibitors and AII-antagonists. These drugs add to cardiovascular protection beyond blood pressure and blood glucose control (HOPE, LIFE, CHARM). Interestingly, renal function as well as urinary protein excretion independently contribute to the above classical risk factors for CV morbidity and mortality. In fact, serum creatinine (GFR) and proteinuria are in many studies both in the general population, as well as in other risk groups such as hypertensives, the strongest predictors of CV risk. Recent data have shown that if one targets the kidney with renoprotective antihypertensive therapies such as ACE-inhibitors and AIIA antagonist (IRMA2, IDNT, RENAAL), one may also protect the heart. In fact, unpublished data show that the more one protects the kidney the more one protects the heart. Thus, not only are patients with a compromised renal function (either low GFR or high proteinuria or both) at markedly higher CV risk, they also are responding as good or even better to CV protective therapy. These data urge us to address the question: should we not target and titrate our therapy to improving the kidney to obtain a maximal effect on CV risk. This question is not only relevant in secondary prevention, but certainly also in primary prevention. Data will be presented to make that case. This opens the door for multi-organ disease management and therapy in an ever growing disease 10 "
    "pdfFichero" => "P7-E232-S132-A2967.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/P7-E232-S132-A2967.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029786?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión
D. DE ZEEUW
Leído
5005
Veces
se ha leído el artículo
2117
Total PDF
2888
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699504029786"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 1:10"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2050
    "formatos" => array:3 [
      "EPUB" => 221
      "HTML" => 1380
      "PDF" => 449
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504029778"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:11-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2581
      "formatos" => array:3 [
        "EPUB" => 227
        "HTML" => 1872
        "PDF" => 482
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Efecto del losartan sobre la muerte cardíaca súbita en personas con diabetes: estudio LIFE"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "11"
          "paginaFinal" => "12"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L. LINDHOLM"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "L. LINDHOLM"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029778?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029778/v0_201502091335/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504029794"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 1:8-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3584
      "formatos" => array:3 [
        "EPUB" => 259
        "HTML" => 2623
        "PDF" => 702
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Óxido nítrico y remodelación vascular: papel de las metalopreatasas de matriz extracelular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "8"
          "paginaFinal" => "9"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "S. LAMAS , C. ZARAGOZA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "S. LAMAS , C. ZARAGOZA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029794?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029794/v0_201502091335/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "10"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "D. DE ZEEUW"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "D. DE ZEEUW"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXIV. Número Extraordinario (I). 2004 Terapia organoprotectora antihipertensiva para pacientes con enfermedad renal e hipertensión D. de Zeeuw University Medical Center. Groningen. The Netherlands. Patients with renal disease not only run a great risk of end-stage-renal failure, but also high risk for cardiovascular morbidity and mortality. Indeed, a decreased glomerular filtration rate or a excessive leak of proteins in the urine are prime risk markers for CV morbidity and mortality. As far as protein leaks are concerned, even low range leakage called microalbuminuria (30-300 mg/day) appears to be such a marker. The classical cardiovascular risk profiling is based on glucose metabolism (diabetes), blood pressure, cholesterol, smoking (overweight, and lifestyle). These parameters not only allow us to classify the risk of a patient in the office, but they also allowed us to justify our therapeutic strategies. These therapies are aimed at reducing these risk factors/markers. Indeed, metabolic control of glucose was a big step in preventing the life threatening end-organ effects of type 2 diabetes. Even more impressive effects were seen when one controls blood pressure on end-organ damage. Recently, lowering of cholesterol has been added to this cardiovascular protective armamentarium. By far the biggest additive step has been made recently by the introduction of tools to intervene in the renin-angiotensin-aldosteron system, such as ACE-inhibitors and AII-antagonists. These drugs add to cardiovascular protection beyond blood pressure and blood glucose control (HOPE, LIFE, CHARM). Interestingly, renal function as well as urinary protein excretion independently contribute to the above classical risk factors for CV morbidity and mortality. In fact, serum creatinine (GFR) and proteinuria are in many studies both in the general population, as well as in other risk groups such as hypertensives, the strongest predictors of CV risk. Recent data have shown that if one targets the kidney with renoprotective antihypertensive therapies such as ACE-inhibitors and AIIA antagonist (IRMA2, IDNT, RENAAL), one may also protect the heart. In fact, unpublished data show that the more one protects the kidney the more one protects the heart. Thus, not only are patients with a compromised renal function (either low GFR or high proteinuria or both) at markedly higher CV risk, they also are responding as good or even better to CV protective therapy. These data urge us to address the question: should we not target and titrate our therapy to improving the kidney to obtain a maximal effect on CV risk. This question is not only relevant in secondary prevention, but certainly also in primary prevention. Data will be presented to make that case. This opens the door for multi-organ disease management and therapy in an ever growing disease 10 "
    "pdfFichero" => "P7-E232-S132-A2967.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35393"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Artículos Originales"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S1/v0_201502091335/X0211699504029786/v0_201502091335/en/P7-E232-S132-A2967.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504029786?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 7 6 13
2024 Octubre 30 32 62
2024 Septiembre 35 28 63
2024 Agosto 32 61 93
2024 Julio 37 32 69
2024 Junio 57 32 89
2024 Mayo 41 33 74
2024 Abril 43 34 77
2024 Marzo 25 15 40
2024 Febrero 26 36 62
2024 Enero 34 23 57
2023 Diciembre 25 32 57
2023 Noviembre 34 30 64
2023 Octubre 30 43 73
2023 Septiembre 20 29 49
2023 Agosto 32 22 54
2023 Julio 29 31 60
2023 Junio 25 27 52
2023 Mayo 48 26 74
2023 Abril 20 24 44
2023 Marzo 23 16 39
2023 Febrero 24 30 54
2023 Enero 24 24 48
2022 Diciembre 36 39 75
2022 Noviembre 31 34 65
2022 Octubre 27 50 77
2022 Septiembre 33 26 59
2022 Agosto 36 42 78
2022 Julio 29 45 74
2022 Junio 22 32 54
2022 Mayo 30 37 67
2022 Abril 28 36 64
2022 Marzo 35 41 76
2022 Febrero 21 35 56
2022 Enero 23 40 63
2021 Diciembre 35 45 80
2021 Noviembre 24 40 64
2021 Octubre 17 33 50
2021 Septiembre 25 45 70
2021 Agosto 21 34 55
2021 Julio 24 26 50
2021 Junio 9 25 34
2021 Mayo 24 29 53
2021 Abril 23 56 79
2021 Marzo 23 23 46
2021 Febrero 17 17 34
2021 Enero 30 21 51
2020 Diciembre 11 15 26
2020 Noviembre 22 8 30
2020 Octubre 17 13 30
2020 Septiembre 9 12 21
2020 Agosto 28 9 37
2020 Julio 13 16 29
2020 Junio 9 17 26
2020 Mayo 25 24 49
2020 Abril 18 15 33
2020 Marzo 19 14 33
2020 Febrero 22 14 36
2020 Enero 27 17 44
2019 Diciembre 27 24 51
2019 Noviembre 22 15 37
2019 Octubre 10 9 19
2019 Septiembre 14 13 27
2019 Agosto 6 14 20
2019 Julio 12 29 41
2019 Junio 15 11 26
2019 Mayo 15 27 42
2019 Abril 37 35 72
2019 Marzo 12 22 34
2019 Febrero 7 11 18
2019 Enero 16 14 30
2018 Diciembre 29 24 53
2018 Noviembre 37 13 50
2018 Octubre 48 11 59
2018 Septiembre 24 12 36
2018 Agosto 21 9 30
2018 Julio 21 8 29
2018 Junio 15 9 24
2018 Mayo 28 13 41
2018 Abril 16 8 24
2018 Marzo 15 9 24
2018 Febrero 27 2 29
2018 Enero 11 6 17
2017 Diciembre 22 4 26
2017 Noviembre 12 7 19
2017 Octubre 18 4 22
2017 Septiembre 13 7 20
2017 Agosto 11 4 15
2017 Julio 10 4 14
2017 Junio 8 5 13
2017 Mayo 14 4 18
2017 Abril 19 5 24
2017 Marzo 10 8 18
2017 Febrero 18 5 23
2017 Enero 6 3 9
2016 Diciembre 7 4 11
2016 Noviembre 13 5 18
2016 Octubre 17 2 19
2016 Septiembre 25 3 28
2016 Agosto 66 1 67
2016 Julio 85 3 88
2016 Junio 48 0 48
2016 Mayo 58 0 58
2016 Abril 26 0 26
2016 Marzo 28 0 28
2016 Febrero 36 0 36
2016 Enero 33 0 33
2015 Diciembre 55 0 55
2015 Noviembre 44 0 44
2015 Octubre 23 0 23
2015 Septiembre 38 0 38
2015 Agosto 43 0 43
2015 Julio 20 0 20
2015 Junio 16 0 16
2015 Mayo 11 0 11
2015 Abril 6 0 6
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?